Immune Pharmaceuticals is a clinical stage, publicly funded bio-pharmaceutical company focused on antibody therapeutics for the treatment of inflammatory diseases and cancer. Bertilimumab, the Company’s lead product candidate, is currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn’s disease (CD) and bullous pemphigoid (BP). Severe asthma is another promising potential application for bertilimumab. The Company is also developing the NanomAb platform, an antibody-conjugated, chemotherapy-loaded nanoparticle, to specifically target cancer drugs to cancer cells, with the goal of producing greater efficacy while reducing off-target effects. The Company’s pipeline also includes antibodies and small molecules, primarily to support the development of NanomAb drug candidates for various tumor types. AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies, has shown efficacy in Phase II trials and has received Fast Track designation for a Phase III trial in chemotherapy induced peripheral neuropathy.